BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing
Jun 10
U.S. Biotech Industry Analysis
UpdatedJun 10, 2024
DataAggregated Company Financials
Companies570
- 7D3.0%
- 3M-3.3%
- 1Y8.3%
- YTD2.2%
The Biotech industry is up 3.0% in the last week, with AbbVie up 5.8%. This means that the industry has gained 8.3% over the past year. As for the next few years, earnings are expected to grow by 25% per annum.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 10 Jun 2024 | US$1.2t | US$164.5b | -US$26,798,622,131.21 | 28.1x | -43.1x | 7x |
| Wed, 08 May 2024 | US$1.1t | US$163.1b | -US$27,148,218,752.30 | 25.7x | -41.4x | 6.9x |
| Fri, 05 Apr 2024 | US$1.1t | US$164.3b | -US$23,437,244,791.39 | 23.1x | -48.9x | 7x |
| Sun, 03 Mar 2024 | US$1.2t | US$167.9b | -US$21,319,237,627.75 | 15.9x | -56.5x | 7.2x |
| Tue, 30 Jan 2024 | US$1.4t | US$204.7b | -US$22,656,479,710.00 | 18.6x | -63.1x | 7x |
| Thu, 28 Dec 2023 | US$1.4t | US$204.9b | -US$22,182,372,574.00 | 19.7x | -62.7x | 6.8x |
| Sat, 25 Nov 2023 | US$1.2t | US$204.8b | -US$22,015,480,281.00 | 18.6x | -55.7x | 6x |
| Mon, 23 Oct 2023 | US$1.2t | US$207.4b | -US$13,059,770,915.00 | 16.6x | -93.9x | 5.9x |
| Wed, 20 Sep 2023 | US$1.3t | US$207.5b | -US$12,859,428,048.00 | 16.9x | -99.9x | 6.2x |
| Fri, 18 Aug 2023 | US$1.3t | US$207.7b | -US$12,279,921,044.00 | 17.5x | -103.5x | 6.1x |
| Sun, 16 Jul 2023 | US$1.1t | US$186.7b | -US$15,968,283,125.00 | 12.9x | -71.1x | 6.1x |
| Tue, 13 Jun 2023 | US$1.2t | US$186.0b | -US$15,957,784,646.00 | 11.8x | -72.2x | 6.2x |
| Thu, 11 May 2023 | US$1.2t | US$191.8b | -US$11,888,575,254.00 | 14.5x | -97.7x | 6.1x |
| Sat, 08 Apr 2023 | US$1.2t | US$216.8b | -US$5,729,503,829.00 | 14x | -203x | 5.4x |
| Mon, 06 Mar 2023 | US$1.2t | US$199.0b | -US$4,959,714,454.00 | 16.5x | -232.4x | 5.8x |
| Wed, 01 Feb 2023 | US$1.2t | US$203.8b | US$1.8b | 15.1x | 660.3x | 5.7x |
| Fri, 30 Dec 2022 | US$1.1t | US$203.4b | US$1.8b | 14.3x | 646.9x | 5.6x |
| Sun, 27 Nov 2022 | US$1.1t | US$202.3b | US$1.3b | 14.6x | 845.5x | 5.6x |
| Tue, 25 Oct 2022 | US$1.1t | US$206.2b | US$5.3b | 15.8x | 200.9x | 5.2x |
| Thu, 22 Sep 2022 | US$1.0t | US$206.3b | US$5.7b | 14x | 179.3x | 5x |
| Sat, 20 Aug 2022 | US$1.1t | US$206.4b | US$7.3b | 16x | 147.7x | 5.2x |
| Mon, 18 Jul 2022 | US$1.1t | US$211.3b | US$10.6b | 17.2x | 102.8x | 5.2x |
| Wed, 15 Jun 2022 | US$918.0b | US$212.1b | US$10.9b | 14.5x | 84.3x | 4.3x |
| Fri, 13 May 2022 | US$938.1b | US$210.6b | US$12.5b | 12.8x | 75.3x | 4.5x |
| Sun, 10 Apr 2022 | US$1.3t | US$226.8b | US$14.3b | 18.8x | 92.1x | 5.8x |
| Tue, 08 Mar 2022 | US$1.2t | US$221.8b | US$10.5b | 19.1x | 114.3x | 5.4x |
| Thu, 03 Feb 2022 | US$1.3t | US$212.2b | US$1.4b | 23x | 905.7x | 6x |
| Sat, 01 Jan 2022 | US$1.4t | US$212.1b | US$2.8b | 25.5x | 509.6x | 6.7x |
| Mon, 29 Nov 2021 | US$1.5t | US$211.9b | US$3.2b | 25x | 461x | 6.9x |
| Wed, 27 Oct 2021 | US$1.5t | US$196.3b | -US$2,785,330,179.00 | 24x | -538.6x | 7.6x |
| Fri, 24 Sep 2021 | US$1.6t | US$196.3b | -US$2,201,769,722.00 | 25.4x | -722.1x | 8.1x |
| Sun, 22 Aug 2021 | US$1.5t | US$197.0b | -US$1,662,914,785.58 | 22.1x | -923.9x | 7.8x |
| Fri, 09 Jul 2021 | US$1.5t | US$196.9b | -US$825,939,314.84 | 25.2x | -1810.8x | 7.6x |
Price to Earnings Ratio
-1810.8x
Current Industry PE
- Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 6.2x is lower than the industry's current PS ratio of 7.0x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Revenues have also declined 5.8% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 0.84% | |
| Healthcare | 1.84% | |
| Biotech | 3.00% | |
| Biotech | 3.00% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ABBV AbbVie | US$169.42 | 5.8% +US$16.3b | 23.0% | PE50.3x | |
| VRTX Vertex Pharmaceuticals | US$483.04 | 2.7% +US$3.3b | 41.8% | PE31x | |
| SGEN Seagen | US$228.74 | 4.5% +US$1.8b | 76.5% | PS18.8x | |
| GILD Gilead Sciences | US$64.70 | 2.0% +US$1.6b | -16.9% | PE166.2x | |
| REGN Regeneron Pharmaceuticals | US$1.00k | 1.4% +US$1.5b | 33.0% | PE28x |
